- The S&P/ASX 200 Health Care closed on Monday with a gain of 1.25%.
- The healthcare index has lost 1.55% over this month.
- RSH, AVR, and NTI are three stocks from ASX healthcare that have outperformed the healthcare index and are up by more than 15% this month.
The S&P/ASX200 closed on Monday, gaining 127.30 points or 1.94% to 6,706.00. The index has gained 4.24% over the last five days but is down 9.92% on a year-to-date basis. Aligning with the ASX benchmark, the S&P/ASX 200 Healthcare also closed on Monday with a gain of 1.25%. The index is down 10.97% YTD and has lost 1.55% over this month.
Today, in this article we will look at three stocks from ASX healthcare - RSH, AVR, and NTI which have racked up over 15% gains this month and have outperformed the healthcare index.
Data source: Refinitiv as of 27 June 2022
Respiri Limited (ASX:RSH)
Respiri Limited is a medical technology company that assists respiratory health management. The company boasts a world-first technology that provides an objective measure of airway limitation by detecting wheeze, a typical symptom of asthma, Chronic Obstructive Pulmonary Disease (COPD) and other respiratory diseases.
Recently, Respiri appointed Brad Snow, a leading US med-tech executive, as a Non-Executive Director of the company. With proven success in leading emerging health technology companies, Mr Snow holds an in-depth experience in the US healthcare industry,
In the March 2022 quarter, the company was majorly focused on the US market with resource and investment strategies in place.
Anteris Technologies Ltd (ASX: AVR)
Anteris Technologies Ltd is a structural heart company, which is focused on developing next-generation technologies to provide life-changing outcomes for patients. The company’s lead product is Anteris’ DurAVR™ 3D, a single-piece aortic heart valve replacement.
Recently, the company reported encouraging results from its DurAVR™ in the first group of patients at the six-month mark. It was an informal follow-up in which DurAVR™ demonstrated continued excellent haemodynamics, resulting in a dramatic enhancement in patients’ ability to exercise, etc.
Neurotech International Limited (ASX: NTI)
Neurotech is conducting clinical studies to assess the anti-inflammatory, neuroprotective, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains. The company has submitted major provisional patents regarding the composition and usage of NTI164 for curing different types of neurological disorders.
Recently, Neurotech reported encouraging results from preclinical research. The study demonstrated significant anti-inflammatory synergistic action of NTI164, when coupled with Diclofenac at low doses.
Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used in curing different pain and inflammatory conditions.